{
    "nct_id": "NCT03122457",
    "official_title": "Improvement of Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide 1.2%/3.75% Combination Gel",
    "inclusion_criteria": "* Women 18 years or older\n* Women who have had their first menses at least 12 months ago, and who currently have regular menses.\n* Subjects must be able to read and understand English, and be able and willing to complete the survey.\n* Subjects must have a self-reported complaint of peri-menstrual acne which has occurred monthly for the last 6 months.\n* Subjects must be willing to forego any other therapy to the treatment area for the duration of the study.\n* Subject is willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up periods and to comply with all study requirements including concomitant medication and other treatment restrictions.\n* Subjects must have a negative urine pregnancy test result prior to study treatment initiation and must agree to use an approved method of birth control while enrolled in the study.\n* Subjects must be willing to use a form of birth control during the study. For the purpose of this study, the following are considered acceptable methods of birth control: oral contraceptives, Norplant, Depo-Provera, double barrier methods (e.g., condom and spermicide) and abstinence.\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Male subjects.\n* Post-menopausal women.\n* Women who do not suffer from acne.\n* Subjects who are allergic to clindamycin, benzoyl peroxide, lidocaine or any other ingredients listed in the study medication.\n* Subjects with an unstable medical condition as deemed by the clinical investigator.\n* Subjects with ulcerative colitis or Crohn's disease.\n* Subjects with any dermatologic disease in the treatment area that may be exacerbated by the treatment proposed or that might impair the evaluation of acne.\n* Women who are pregnant, lactating, or planning to become pregnant during the study period.\n* Subjects who have used any topical prescription medications on the study area within 30 days prior to Visit 2 / Baseline.\n* Subjects on a stable dose of oral contraceptives for less than 6 months.",
    "miscellaneous_criteria": ""
}